

# Hanno Glimm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9146160/publications.pdf>

Version: 2024-02-01

71  
papers

6,917  
citations

147801

31  
h-index

98798

67  
g-index

73  
all docs

73  
docs citations

73  
times ranked

8879  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. <i>Nature Medicine</i> , 2006, 12, 401-409.	30.7	1,129
2	Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. <i>Nature Medicine</i> , 2010, 16, 198-204.	30.7	727
3	Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome. <i>New England Journal of Medicine</i> , 2010, 363, 1918-1927.	27.0	505
4	An unbiased genome-wide analysis of zinc-finger nuclease specificity. <i>Nature Biotechnology</i> , 2011, 29, 816-823.	17.5	488
5	Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity. <i>Science Translational Medicine</i> , 2014, 6, 227ra33.	12.4	460
6	High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). <i>Nature Methods</i> , 2007, 4, 1051-1057.	19.0	281
7	Distinct Types of Tumor-Initiating Cells Form Human Colon Cancer Tumors and Metastases. <i>Cell Stem Cell</i> , 2011, 9, 357-365.	11.1	276
8	Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. <i>Journal of Clinical Investigation</i> , 2007, 117, 2225-2232.	8.2	221
9	Integrative genomic and transcriptomic analysis of leiomyosarcoma. <i>Nature Communications</i> , 2018, 9, 144.	12.8	197
10	<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer. <i>Cancer Discovery</i> , 2018, 8, 1087-1095.	9.4	189
11	Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. <i>Journal of Clinical Investigation</i> , 2007, 117, 2241-2249.	8.2	185
12	Comprehensive genomic access to vector integration in clinical gene therapy. <i>Nature Medicine</i> , 2009, 15, 1431-1436.	30.7	173
13	Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. <i>Nature Protocols</i> , 2010, 5, 1379-1395.	12.0	161
14	The tRNA methyltransferase Dnmt2 is required for accurate polypeptide synthesis during haematopoiesis. <i>EMBO Journal</i> , 2015, 34, 2350-2362.	7.8	154
15	Precision oncology based on omics data: The NCT Heidelberg experience. <i>International Journal of Cancer</i> , 2017, 141, 877-886.	5.1	133
16	Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. <i>ESMO Open</i> , 2016, 1, e000094.	4.5	126
17	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	9.4	125
18	High-resolution analysis of the human T-cell receptor repertoire. <i>Nature Communications</i> , 2015, 6, 8081.	12.8	123

#	ARTICLE	IF	CITATIONS
19	Recurrent CDKN1B (p27) mutations in hairy cell leukemia. <i>Blood</i> , 2015, 126, 1005-1008.	1.4	88
20	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1177-1189.	1.1	81
21	The landscape of chromothripsis across adult cancer types. <i>Nature Communications</i> , 2020, 11, 2320.	12.8	75
22	Cell-of-Origin DNA Methylation Signatures Are Maintained during Colorectal Carcinogenesis. <i>Cell Reports</i> , 2018, 23, 3407-3418.	6.4	66
23	The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. <i>Leukemia</i> , 2017, 31, 1570-1581.	7.2	60
24	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplification. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001180.	1.2	57
25	Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. <i>Leukemia</i> , 2016, 30, 937-946.	7.2	52
26	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. <i>Oncolmmunology</i> , 2017, 6, e1279777.	4.6	50
27	Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer. <i>Cell Reports</i> , 2017, 20, 1906-1920.	6.4	49
28	Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. <i>Cell Reports</i> , 2021, 36, 109394.	6.4	41
29	Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. <i>EMBO Molecular Medicine</i> , 2017, 9, 918-932.	6.9	36
30	Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. <i>Blood</i> , 2005, 106, 893-898.	1.4	33
31	Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 4, 213-224.	4.1	32
32	YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis. <i>Cancer Research</i> , 2020, 80, 5502-5514.	0.9	31
33	Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. <i>Journal of Experimental Medicine</i> , 2017, 214, 2073-2088.	8.5	30
34	Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. <i>Annals of Oncology</i> , 2017, 28, 142-148.	1.2	30
35	Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 962-973.	7.0	29
36	Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. <i>PLoS ONE</i> , 2019, 14, e0211916.	2.5	27

#	ARTICLE	IF	CITATIONS
37	Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. <i>International Journal of Cancer</i> , 2017, 140, 1356-1363.	5.1	26
38	A Model for the Detection of Clonality in Marked Hematopoietic Stem Cells. <i>Annals of the New York Academy of Sciences</i> , 2001, 938, 146-156.	3.8	25
39	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group "Molecular Diagnostics and Therapy". <i>European Journal of Cancer</i> , 2020, 135, 1-7.	2.8	23
40	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 2488-2495.	8.2	23
41	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors "TORC1/2 Inhibition as Salvage Strategy. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1985-1996.	4.1	22
42	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	3.0	20
43	So rare we need to hunt for them: reframing the ethical debate on incidental findings. <i>Genome Medicine</i> , 2015, 7, 83.	8.2	19
44	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. <i>Oncogene</i> , 2020, 39, 814-832.	5.9	19
45	Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. <i>Cell Death and Disease</i> , 2020, 11, 875.	6.3	17
46	YAP-induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer. <i>Liver International</i> , 2021, 41, 3011-3023.	3.9	17
47	Pheno-seq "linking visual features and gene expression in 3D cell culture systems. <i>Scientific Reports</i> , 2019, 9, 12367.	3.3	16
48	Mapping Active Gene-Regulatory Regions in Human Repopulating Long-Term HSCs. <i>Cell Stem Cell</i> , 2018, 23, 132-146.e9.	11.1	14
49	Stk33 is required for spermatid differentiation and male fertility in mice. <i>Developmental Biology</i> , 2018, 433, 84-93.	2.0	13
50	Colorectal cancer-initiating cells caught in the act. <i>EMBO Molecular Medicine</i> , 2017, 9, 856-858.	6.9	12
51	Stable Long-Term Blood Formation by Stem Cells in Murine Steady-State Hematopoiesis. <i>Stem Cells</i> , 2012, 30, 1961-1970.	3.2	11
52	Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. <i>Cancer Letters</i> , 2016, 371, 326-333.	7.2	11
53	Genomics of Immunotherapy-Associated Hyperprogressors"Letter. <i>Clinical Cancer Research</i> , 2017, 23, 6374-6375.	7.0	11
54	Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. <i>Pancreatology</i> , 2020, 20, 425-432.	1.1	11

#	ARTICLE	IF	CITATIONS
55	Functional States in Tumor-Initiating Cell Differentiation in Human Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1097.	3.7	11
56	You Can Count on This: Barcoded Hematopoietic Stem Cells. <i>Cell Stem Cell</i> , 2011, 9, 390-392.	11.1	10
57	Induction of the proapoptotic tumor suppressor gene <i>Cell Adhesion Molecule 1</i> by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia. <i>Molecular Carcinogenesis</i> , 2015, 54, 1815-1819.	2.7	9
58	Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer. <i>Cells</i> , 2019, 8, 142.	4.1	9
59	High-throughput monitoring of integration site clonality in preclinical and clinical gene therapy studies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 14061.	4.1	8
60	Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing. <i>Cancers</i> , 2020, 12, 3627.	3.7	7
61	Sustained Polyclonal Hematopoietic Repopulation after Successful SCID-X1 Gene Therapy by Means of a Non Random Integrating Pseudotyped Gammaretrovector.. <i>Blood</i> , 2004, 104, 290-290.	1.4	7
62	High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. <i>British Journal of Dermatology</i> , 2021, , .	1.5	6
63	Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare) Tj ETQq1 1 0.784314 rgBT /Overlock 1	4.5	6
64	A perivascular niche in the bone marrow hosts quiescent and proliferating tumorigenic colorectal cancer cells. <i>International Journal of Cancer</i> , 2020, 147, 519-531.	5.1	5
65	Ruxolitinib is effective in the treatment of a patient with refractory Tâ€ALL. <i>EJHaem</i> , 2021, 2, 139-142.	1.0	4
66	Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With <i>ETV6-NTRK3</i> Fusion-Positive Carcinoma Harboring the <i>NTRK3</i> <sup>G623R</sup> Solvent-Front Mutation. <i>JCO Precision Oncology</i> , 2021, 5, 687-694.	3.0	3
67	<i>MGMT</i> inactivation as a new biomarker in patients with advanced biliary tract cancers. <i>Molecular Oncology</i> , 2022, 16, 2733-2746.	4.6	2
68	Persistence of eGFP Marked Bone Marrow Cells in Long-Term Hematopoiesis.. <i>Blood</i> , 2004, 104, 2111-2111.	1.4	0
69	Insertional Activation of <i>MDS1/EVI1</i> , <i>PRDM16</i> and <i>SETBP1</i> in a Successful Chronic Granulomatous Disease (CGD) Gene Therapy Trial.. <i>Blood</i> , 2006, 108, 3274-3274.	1.4	0
70	Deregulated <i>EVI1</i> Expression Leads to Genomic Instability and G1 Cell Cycle Arrest. <i>Blood</i> , 2011, 118, 2431-2431.	1.4	0
71	Recurrent Germline Variant in the Cohesin Complex Gene <i>RAD21</i> Predisposes Children to Lymphoblastic Leukemia and Lymphoma. <i>Blood</i> , 2021, 138, 3358-3358.	1.4	0